Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy Day 1 of tipifarnib therapy to week 8 [clinicaltrials_resource:f2782976d175084cda8338a094a33dce]
The dose limiting toxicity (DLT) analysis population consists of phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (courses 1 and 2) or who completed the MTD estimation period (courses 1 and 2) without DLTs. DLTs observed during courses 1 and 2 were used to estimate the MTD.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy Day 1 of tipifarnib therapy to week 8 [clinicaltrials_resource:f2782976d175084cda8338a094a33dce]
The dose limiting toxicity (DLT) analysis population consists of phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (courses 1 and 2) or who completed the MTD estimation period (courses 1 and 2) without DLTs. DLTs observed during courses 1 and 2 were used to estimate the MTD.
Bio2RDF identifier
f2782976d175084cda8338a094a33dce
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f2782976d175084cda8338a094a33dce
measure [clinicaltrials_vocabulary:measure]
Number of Participants in the ...... 1 and 2) of Tipifarnib Therapy
time frame [clinicaltrials_vocabulary:time-frame]
Day 1 of tipifarnib therapy to week 8
description
The dose limiting toxicity (DL ...... were used to estimate the MTD.
identifier
clinicaltrials_resource:f2782976d175084cda8338a094a33dce
title
Number of Participants in the ...... f tipifarnib therapy to week 8
@en
type
label
Number of Participants in the ...... 82976d175084cda8338a094a33dce]
@en